Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026)

Compass Therapeutics has disclosed Return on Capital Employed across 8 years of filings, most recently posting 37.2% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 37.2%, up 1389.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 37.2% (up 1389.0% YoY), and the FY2025 annual result was 43.87%, down 336.0% from the prior year.
• Return on Capital Employed came in at 37.2% for Q1 2026 at Compass Therapeutics, down from 34.45% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 23.7% in Q1 2022 to a low of 61.56% in Q2 2025.
• The 5-year median for Return on Capital Employed is 34.44% (2024), against an average of 35.55%.
• Across the five-year window, Return on Capital Employed soared 4568 bps in 2022 and slumped 2452 bps in 2025, its largest moves.
• Compass Therapeutics' Return on Capital Employed stood at 28.23% in 2022, then dropped by 15 bps to 32.36% in 2023, then fell by 29 bps to 41.67% in 2024, then rose by 17 bps to 34.45% in 2025, then fell by 8 bps to 37.2% in 2026.
• The last three Return on Capital Employed figures came in at 37.2% (Q1 2026), 34.45% (Q4 2025), and 44.21% (Q3 2025), per Business Quant data.